Seminars in Oncology
Volume 31, Issue 4 , Pages 566-573 , August 2004

Treatment of localized gastric cancer

  • John S. Macdonald

      Affiliations

    • Gastrointestinal Oncology Service, Saint Vincent’s Comprehensive Cancer Center, New York, NY, USA
    • Corresponding Author Information Address reprint requests to John S. Macdonald, MD, Gastrointestinal Oncology Sevice, St. Vincent’s Comprehensive Cancer Center, 325 W 15th St, New York, NY 10011 USA

References 

  1. Bonenkamp JJ, Hermans J, Sasako M. Extended lymph node dissection for gastric cancer. N Engl J Med. 1999;340:908–914
  2. Kodama Y, Sugimachi K, Soejima K, et al.  Evaluation of extensive lymph node dissection for carcinoma of the stomach. World J Surg. 1981;5:241–248
  3. Vezerdis MP, Wanebo HJ. Gastric cancer (Surgical approach). In:  Ahlgren JD,  Macdonald JS editor. Gastrointestinal Oncology. Philadelphia, PA: Lippincott; 1992;p. 159–170
  4. Robertson CS, Chung SCS, Woods SDS, et al.  A prospective randomized trial comparing R1 subtotal gastrectomy for antral cancer. Ann Surg. 1994;220:176
  5. Bunt AMG, Hermans J, Smit VT. Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol. 1995;13:19–25
  6. Hermans J, Bonenkamp JJ, Boon MC, et al.  Adjuvant therapy after curative resection for gastric cancer (Meta-analysis of randomized trials). J Clin Oncol. 1993;11:1441–1447
  7. Macdonald JS, Fleming TR, Peterson RF, et al.  Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma (A Southwest Oncology Group Study). Ann Surg Oncol. 1995;2:488–494
  8. Cascinu S, Labianca R, Allesandroni P, et al.  Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim (A report from the Italian Group for the Study of Digestive Tract Cancer). J Clin Oncol. 1997;15:3313–3319
  9. Cookes P, Leichman CG, Leichman L, et al.  Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy. Cancer. 1997;79:1767–1775
  10. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg. 1998;75:110
  11. Ilson DH, Saltz L, Enzinger P, et al.  Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol. 1999;17:3270–3725
  12. Kelsen D, Atiq OT, Saltz L, et al.  FAMTX versus etoposide, doxorubicin, and cisplatin (A random assignment trial in gastric cancer). J Clin Oncol. 1992;10:541–548
  13. Kettner E, Ridwelski K, Keilholz U, et al.  Docetaxel and cisplatin combination chemotherapy for advanced gastric cancer (Results of two phase II studies). Proc Am Soc Clin Oncol. 2001;20:165a; (abstr)
  14. Preusser P, Wilke H, Achterrath W, et al.  Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol. 1989;7:1310–1317
  15. Webb A, Cunningham D, Scarffe JH, et al.  Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15:261–267
  16. Wils J, Beliberg H, Blijham G, et al.  An EORTC gastrointestinal evaluation of the combination of sequential methotrexate, and 5-fluorouracil combined with Adriamycin, in advanced measurable gastric cancer. J Clin Oncol. 1986;4:1799–1803
  17. Wils JA, Klein HO, Wagener DJT, et al.  Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: A step ahead in the treatment of advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991;9:827–831
  18. Allum W, Cunningham D, Weeden S, et al.  Perioperative chemotherapy in operable gastric and lower oesophageal cancer (A randomized, controlled trial (the MAGIC trial, ISRCTN 93793971)). Proc Am Soc Clin Oncol. 2003;22:249a; (abstr 998)
  19. Ross P, Cunningham D, Scarffe H. Results of a randomized trial comparing ECF with MCF in advanced oesophageal gastric cancer. Proc Am Soc Clin Oncol. 1999;18:272a; (abstr)
  20. Ajani JA, Van Cutsem E, Moiseyenko V, et al.  Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC) (Interim results of a randomized phase III trial). Proc Am Soc Clin Oncol. 2003;22:249a; (abstr 999)
  21. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients (Revisiting a meta-analysis of randomized trials). Eur J Cancer. 1999;35:1059–1064
  22. Gastrointestinal Tumor Study Group . A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Cancer. 1982;49:1771–1777
  23. Herskovic A, Martz K, Al-Sarraf M, et al.  Combined chemotherapy and radiotherapy compared to radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–1598
  24. Macdonald JS, Smalley SR, Benedetti J, et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–730
  25. Atiq OT, Kelsen DP, Shiu MH. Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. J Clin Oncol. 1993;11:425–433
  26. Markman M. Role of intraperitoneal chemotherapy in the front-line setting. J Clin Oncol. 2003;21(suppl):145s–148s
  27. Saltz L, Rubin M, Hochster H, et al.  Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer that expresses epidermal growth factor receptor. Proc Am Soc Clin Oncol. 2001;20:3a; (abstr 7)
  28. Anido J, Albanell J, Rojo F. Inhibition by ZD1839 (Iressa) of epidermal growth factor and heregulin induced signaling pathways in human breast cancer cells. Proc Am Soc Clin Oncol. 2001;20:429a; (abstr 1712)
  29. Pozzo C, Bugat R, Peschel V, et al.  Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastro-esophageal junction adenocarcinoma (Final results of a randomized phase II study). Proc Am Soc Clin Oncol. 2001;21:134a; (abstr)
  30. Schiessel R, Funovics J, Schick B, et al.  Adjuvant intraperitoneal cisplatin therapy in patients with operated gastric carcinoma (Results of a randomized trial). Acta Med Aust. 1989;16:68–69
  31. Sautner T, Hofnauer F, Depisch D, et al.  Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol. 1994;12:970–974
  32. Hagiwara A, Takahashi T, Kojima O, et al.  Prophylaxis with carbon-adsorbed mitomycin against C in intra-abdominal malignancy. Br J Cancer. 1997;76:1667–1669
  33. Rosen HR, Jatzko G, Repse S, et al.  Adjuvant intraperitoneal chemotherapy with carbon absorbed mitomycin in patients with gastric cancer (results of a randomized multi-center trial of the Austrian Working group for Surgical Oncology). J Clin Oncol. 1998;16:2733–2738
  34. Yu W, Whang I, Chung HY, et al.  Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer (Results of a prospective randomized trial). World J Surg. 2001;25:985–990
  35. Yu W, Whang I, Suh I, et al.  Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg. 1998;228:347–354
  36. Takahashi T, Hagiwara A, Shimotsuma M, et al.  Prophylaxis and treatment of peritoneal carcinomatosis (Intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles). World J Surg. 1995;19:565–569

PII: S0093-7754(04)00243-X

doi: 10.1053/j.seminoncol.2004.04.022

Seminars in Oncology
Volume 31, Issue 4 , Pages 566-573 , August 2004

Article Tools

* Image Usage & Resolution